This volume brings together all aspects of TAXOL® research, development, and clinical use. It provides comprehensive knowledge of the compound and a perspective of the complex interrelationships needed for its development and production. Each chapter is written by an authority in the field. Chapters are carefully coordinated to maximize information on key topics while avoiding overlap and duplication. Previously unpublished material is presented along with thorough reviews of each topic.

Paclitaxel: Sources, Chemistry, Anticancer Actions, and Current Biotechnology provides a comprehensive survey of Paclitaxel and its derivatives chemistry, biosynthesis and anticancer activities. In addition, biotechnological methods, including cell cultures, the use of bioreactors and metabolic engineering strategies to improve Paclitaxel production are also discussed. The book discusses topics such as mechanisms of action against cancer, novel forms of Paclitaxel for an effective cancer treatment, strategies for enhancing its bioavailability, and the application of nanocarriers for its delivery and chemotherapy of cancer. This is a valuable resource for cancer researchers, biotechnologists and members of biomedical field who are interested in the promising anticancer qualities of this antineoplastic drug and how to enhance them for better treatments. - Presents detailed information about Paclitaxel research, from its discovery to clinical uses and biotechnological routes of commercial production - Focuses on Paclitaxel development as an effective chemotherapeutic drug, along with its application in different types of cancers - Encompasses descriptive illustrations and workflows to help the reader fully understand the content and easily apply it to their research

Taxol is arguably the most celebrated, talked-about and controversial natural product in recent years. It is celebrated because of its efficacy as an anti-cancer drug and because its discovery has provided powerful support for policies concerned with biodiversity; talked about because in the late 1980s and early 1990s the American public was bombarded with news reports and special programmes about the molecule and its host, the Pacific yew; and controversial because during the early 1990s the drug and the tree became embroiled in a number of very sensitive political issues with wide implications for the conduct of public policy. The Story of Taxol tells this story.

Written by the foremost authority in the field, this volume is a comprehensive review of the multifaceted phenomenon of hepatotoxicity. Dr. Zimmerman examines the interface between chemicals and the liver; the latest research in experimental hepatotoxicology; the hepatotoxic risks of household, industrial, and environmental chemicals; and the adverse effects of drugs on the liver. This thoroughly revised, updated Second Edition features a greatly expanded section on the wide variety of drugs that can cause liver injury. For quick reference, an appendix lists these medications and their associated hepatic injuries. Also included are in-depth discussions of drug metabolism and factors affecting susceptibility to liver injury.

Edited by three of the world's leading pharmaceutical scientists, this is the first book on this important and hot topic, containing much previously unpublished information. As such, it covers all aspects of green chemistry in the pharmaceutical industry, from simple molecules to complex proteins, and from drug discovery to the fate of pharmaceuticals in the environment. Furthermore, this ready reference contains several convincing case studies from industry, such as Taxol, Pregabalin and Crestor, illustrating how this multidisciplinary approach has yielded efficient and environmentally-friendly processes. Finally, a section on technology and tools highlights the advantages of green chemistry.

Thoroughly updated for its Second Edition, this text provides comprehensive, interdisciplinary coverage of gastrointestinal cancer, including molecular biology, diagnosis, medical, surgical, and radiation therapy, and palliative care. The initial section, Principles of Gastrointestinal Oncology, includes an expanded radiation oncology chapter, an extensively revised cancer genetics chapter, and a completely rewritten medical oncology chapter emphasizing new agents. Subsequent sections focus on esophageal, gastric, pancreatic, hepatocellular, biliary tree, and colorectal cancer. Coverage of each anatomic site includes epidemiology, screening, and prevention; molecular biology and genetics; pathology; anatomy and staging; and clinical management. The final section on uncommon cancers includes new chapters on neuroendocrine tumors and small bowel cancers. A companion Website provides instant access to the complete, fully searchable text.

This comprehensive encyclopedic reference provides rapid access to focused information on topics of cancer research for clinicians, research scientists and advanced students. Given the overwhelming success of the first edition, which appeared in 2001, and fast development in the different fields of cancer research, it has been decided to publish a second fully revised and expanded edition. With an A-Z format of over 7,000 entries, more than 1,000 contributing authors provide a complete reference to cancer. The merging of different basic and clinical scientific disciplines towards the common goal of fighting cancer makes such a comprehensive reference source all the more timely.

This volume brings together all aspects of TAXOL® research, development, and clinical use. It provides comprehensive knowledge of the compound and a perspective of the complex interrelationships needed for its development and production. Each chapter is written by an authority in the field. Chapters are carefully coordinated to maximize information on key topics while avoiding overlap and duplication. Previously unpublished material is presented along with thorough reviews of each topic.